Isoform-Selective Histone Deacetylase Inhibitors

Title: Isoform-Selective Histone Deacetylase Inhibitors

Volume: 14 Issue: 6

Author(s): Takayoshi Suzuki, Yukihiro Itoh and Naoki Miyata

Affiliation:

Keywords: Histone deacetylase, HDAC inhibitors, SIRT inhibitors, isoform-selective inhibitors

Abstract: Histone deacetylases (HDACs) catalyze the deacetylation of the acetylated lysine residues of histones and non-histone proteins, and are involved in various fundamental life phenomena, such as gene expression and cell cycle progression. Thus far, eighteen HDAC family members have been identified and they can be divided into two categories, i.e., zinc-dependent enzymes (HDAC1-11) and NAD+-dependent enzymes (SIRT1-7). Some of the HDAC isoforms have important roles in cell functions, and are associated with various disease states, including cancer. Therefore, isoform-selective HDAC inhibitors are of great interest, not only as tools for probing the biological functions of the isoforms, but also as candidate therapeutic agents with few side effects. In this review, we cover isoformselective HDAC inhibitors, including their biochemical and pharmacological functions.

Cite this article as:

Suzuki Takayoshi, Itoh Yukihiro and Miyata Naoki, Isoform-Selective Histone Deacetylase Inhibitors, Current Pharmaceutical Design 2008; 14 (6) . https://dx.doi.org/10.2174/138161208783885335